Orchard Therapeutics plc

NasdaqCM:ORTX Stock Report

Market Cap: US$380.1m

Orchard Therapeutics Management

Management criteria checks 4/4

Orchard Therapeutics' CEO is Bobby Gaspar, appointed in Mar 2020, has a tenure of 3.83 years. total yearly compensation is $1.45M, comprised of 39.6% salary and 60.4% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $611.47K. The average tenure of the management team and the board of directors is 2.7 years and 5.6 years respectively.

Key information

Bobby Gaspar

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage39.6%
CEO tenure3.8yrs
CEO ownership0.2%
Management average tenure2.7yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

May 09
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Mar 10
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Aug 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14
Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03
What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08
Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11
Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

CEO Compensation Analysis

How has Bobby Gaspar's remuneration changed compared to Orchard Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$85m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$1mUS$573k

-US$151m

Sep 30 2022n/an/a

-US$179m

Jun 30 2022n/an/a

-US$168m

Mar 31 2022n/an/a

-US$154m

Dec 31 2021US$4mUS$605k

-US$145m

Sep 30 2021n/an/a

-US$142m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$137m

Dec 31 2020US$4mUS$543k

-US$152m

Sep 30 2020n/an/a

-US$164m

Jun 30 2020n/an/a

-US$180m

Mar 31 2020n/an/a

-US$183m

Dec 31 2019US$921kUS$344k

-US$163m

Sep 30 2019n/an/a

-US$143m

Jun 30 2019n/an/a

-US$140m

Mar 31 2019n/an/a

-US$246m

Dec 31 2018US$2mUS$338k

-US$230m

Compensation vs Market: Bobby's total compensation ($USD1.45M) is below average for companies of similar size in the US market ($USD2.15M).

Compensation vs Earnings: Bobby's compensation has been consistent with company performance over the past year.

CEO

Bobby Gaspar (60 yo)

3.8yrs

Tenure

US$1,447,526

Compensation

Dr. Hubert Baburaj Gaspar, M.D. Ph.D. also known as Bobby, has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a...

Leadership Team

NamePositionTenureCompensationOwnership
Hubert Gaspar
CEO, Member of Scientific Advisory Board & Executive Director3.8yrsUS$1.45m0.16%
$ 611.5k
Frank Thomas
President & COO4yrsUS$1.21m0.040%
$ 153.8k
Nicoletta Loggia
Chief Technical Officer2.3yrsno datano data
Fulvio Mavilio
Chief Scientific Officer2yrsno datano data
Renee Leck
Head of Investor Relationsno datano datano data
Benjamin Navon
Director of Corporate Communicationsno datano datano data
John Cerio
Chief Human Resource Officerno datano datano data
Robin Kenselaar
Senior VP & GM of EMEA Commercial Operations5.2yrsno datano data
Braden Parker
Chief Commercial Officer3yrsno datano data
Leslie Meltzer
Chief Medical Officer2.3yrsno datano data
Christopher York
Company Secretary1.9yrsno datano data

2.7yrs

Average Tenure

Experienced Management: ORTX's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hubert Gaspar
CEO, Member of Scientific Advisory Board & Executive Director7.9yrsUS$1.45m0.16%
$ 611.5k
James Arthur Geraghty
Independent Chairman5.7yrsUS$107.72k0.019%
$ 74.1k
Marc Dunoyer
Independent Non-Executive Director5.6yrsUS$71.72k0.016%
$ 62.1k
Charles Rowland
Independent Non-Executive Director5.5yrsUS$90.72k0.0054%
$ 20.5k
Donald Kohn
Member of Scientific Advisory Boardno datano datano data
Alessandra Biffi
Member of Scientific Advisory Boardno datano datano data
Brian Bigger
Member of Scientific Advisory Boardno datano datano data
Simon Jones
Member of Scientific Advisory Boardno datano datano data
Adrian Thrasher
Member of Scientific Advisory Boardno datano datano data
David Williams
Member of Scientific Advisory Boardno datano datano data
Robert Wynn
Member of Scientific Advisory Boardno datano datano data
Harry Malech
Member of Scientific Advisory Boardno datano datano data

5.6yrs

Average Tenure

67yo

Average Age

Experienced Board: ORTX's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/24 11:45
End of Day Share Price 2024/01/24 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Orchard Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles DuncanCantor Fitzgerald & Co.
Emma NealonCantor Fitzgerald & Co.
Graig SuvannavejhGoldman Sachs